论文部分内容阅读
中国是甲型病毒性肝炎(甲肝)、乙型病毒性肝炎(乙肝)高发区,病毒的感染和疾病的流行已对人群健康构成了严重威胁。为减少预防接种的注射次数和漏种机会,提高及时接种率和受种者的依从性,多价联合疫苗已在预防接种中推广应用。甲肝和乙肝联合疫苗(Hepatitis A+B Combined Vaccine,HepA+B)的研制成功和应用,为控制甲肝和乙肝提供了新的工具和有效的途径。国内外临床研究结果表明,HepA+B的安全性、免疫原性、稳定性与单价疫苗相当,能够用于预防甲肝和乙肝。
China is a type A viral hepatitis (Hepatitis A) and a high incidence of Hepatitis B (Hepatitis B). The prevalence of viral infections and diseases has posed a serious threat to the health of the population. In order to reduce the number of inoculation vaccination and leakage opportunities, improve the prompt vaccination rate and the compliance of the recipient, multivalent vaccine has been widely used in vaccination. The successful development and application of hepatitis A and B combined vaccine (HepA + B) provide new tools and effective ways to control hepatitis A and B. Clinical studies at home and abroad show that the safety, immunogenicity and stability of HepA + B are comparable to monovalent vaccines and can be used to prevent hepatitis A and B.